Cargando…
Immunogenic Chemotherapy Sensitizes Renal Cancer to Immune Checkpoint Blockade Therapy in Preclinical Models
BACKGROUND: Renal cell carcinoma (RCC) is among the most common malignant cancers of males worldwide. For advanced RCC patients, there still is no effective therapy. Immune checkpoint blockade therapies have shown benefits for many cancers, but previous clinical trials of immune checkpoint blockade...
Autor principal: | Cui, Shujin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516681/ https://www.ncbi.nlm.nih.gov/pubmed/28697172 http://dx.doi.org/10.12659/MSM.902426 |
Ejemplares similares
-
Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade
por: Niewolik, Jacqueline, et al.
Publicado: (2022) -
Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations
por: Principe, Nicola, et al.
Publicado: (2022) -
The Nephroprotective Effect of TNF Receptor-Associated Factor 6 (TRAF6) Blockade on LPS-Induced Acute Renal Injury Through the Inhibition if Inflammation and Oxidative Stress
por: Chen, Xuemei, et al.
Publicado: (2020) -
Neoadjuvant Chemotherapy Improves the Immunosuppressive Microenvironment of Bladder Cancer and Increases the Sensitivity to Immune Checkpoint Blockade
por: Luo, Hao, et al.
Publicado: (2022) -
Inhibitory Effects of Platelet-Rich Plasma on Intervertebral Disc Degeneration: A Preclinical Study in a Rabbit Model
por: Gui, Keke, et al.
Publicado: (2015)